
Lotus Eye Hospital (LOTUSEYE) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
115.1M
Gross Profit
53.3M
46.33%
Operating Income
4.2M
3.62%
Net Income
2.5M
2.19%
Balance Sheet Metrics
Total Assets
695.7M
Total Liabilities
95.7M
Shareholders Equity
600.0M
Debt to Equity
0.16
Cash Flow Metrics
Revenue & Profitability Trend
Lotus Eye Hospital Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 495.6M | 472.4M | 459.8M | 380.9M | 316.7M |
Cost of Goods Sold | 249.0M | 238.2M | 227.3M | 188.3M | 156.5M |
Gross Profit | 246.6M | 234.2M | 232.6M | 192.5M | 160.1M |
Gross Margin % | 49.8% | 49.6% | 50.6% | 50.6% | 50.6% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 19.7M | 20.8M | 15.7M | 8.5M |
Other Operating Expenses | 96.1M | 38.0M | 36.1M | 30.8M | 32.4M |
Total Operating Expenses | 96.1M | 57.7M | 56.9M | 46.5M | 40.9M |
Operating Income | 4.3M | 29.1M | 47.1M | 34.7M | 13.2M |
Operating Margin % | 0.9% | 6.2% | 10.2% | 9.1% | 4.2% |
Non-Operating Items | |||||
Interest Income | - | 5.0M | 4.7M | 4.3M | 3.9M |
Interest Expense | 3.6M | 974.0K | 976.0K | 1.3M | 563.0K |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 13.8M | 40.1M | 56.5M | 40.9M | 19.9M |
Income Tax | 6.4M | 11.0M | 15.7M | 11.1M | 4.2M |
Effective Tax Rate % | 46.5% | 27.4% | 27.9% | 27.1% | 21.3% |
Net Income | 7.4M | 29.1M | 40.8M | 29.8M | 15.7M |
Net Margin % | 1.5% | 6.2% | 8.9% | 7.8% | 5.0% |
Key Metrics | |||||
EBITDA | 47.3M | 78.3M | 87.3M | 67.7M | 43.0M |
EPS (Basic) | - | ₹1.40 | ₹1.96 | ₹1.44 | ₹0.75 |
EPS (Diluted) | - | ₹1.40 | ₹1.96 | ₹1.44 | ₹0.75 |
Basic Shares Outstanding | - | 20796300 | 20796300 | 20796300 | 20796000 |
Diluted Shares Outstanding | - | 20796300 | 20796300 | 20796300 | 20796000 |
Income Statement Trend
Lotus Eye Hospital Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 20.1M | 26.5M | 36.0M | 37.9M | 51.8M |
Short-term Investments | 21.4M | 42.8M | 47.3M | 50.0M | 47.1M |
Accounts Receivable | 13.2M | 12.6M | 11.7M | 6.2M | 7.4M |
Inventory | 38.3M | 32.1M | 27.9M | 23.1M | 17.8M |
Other Current Assets | 22.7M | 25.1M | 23.3M | 10.9M | 11.7M |
Total Current Assets | 115.7M | 140.2M | 147.1M | 128.6M | 136.0M |
Non-Current Assets | |||||
Property, Plant & Equipment | 539.4M | 411.3M | 367.8M | 350.7M | 333.9M |
Goodwill | 1.3M | 744.0K | 1.0M | 1.2M | 1.6M |
Intangible Assets | - | 744.0K | 1.0M | 1.2M | 1.6M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 14.6M | 35.8M | 29.7M | 41.4M | 43.1M |
Total Non-Current Assets | 580.0M | 526.1M | 484.8M | 487.3M | 456.2M |
Total Assets | 695.7M | 666.3M | 631.9M | 616.0M | 592.3M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 33.6M | 34.6M | 31.5M | 35.6M | 28.3M |
Short-term Debt | 14.0M | 4.2M | 4.8M | 5.7M | 2.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 7.2M | 4.0M | 4.2M | 2.1M | 2.7M |
Total Current Liabilities | 74.2M | 62.3M | 51.9M | 57.6M | 58.2M |
Non-Current Liabilities | |||||
Long-term Debt | 20.3M | 6.9M | 1.9M | 6.7M | 1.4M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | - | 2.3M | 2.2M | 2.1M | 1.8M |
Total Non-Current Liabilities | 21.5M | 9.9M | 4.2M | 12.3M | 7.1M |
Total Liabilities | 95.7M | 72.2M | 56.1M | 69.9M | 65.3M |
Equity | |||||
Common Stock | 208.0M | 208.0M | 208.0M | 208.0M | 208.0M |
Retained Earnings | - | 135.7M | 116.9M | 86.6M | 67.1M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 600.0M | 594.1M | 575.8M | 546.1M | 527.0M |
Key Metrics | |||||
Total Debt | 34.3M | 11.1M | 6.7M | 12.4M | 4.0M |
Working Capital | 41.5M | 77.9M | 95.2M | 71.1M | 77.9M |
Balance Sheet Composition
Lotus Eye Hospital Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 13.7M | 40.1M | 56.5M | 41.0M | 19.1M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | -3.5M | -5.3M | -11.9M | -10.0M | -4.0M |
Operating Cash Flow | 5.8M | 26.4M | 36.7M | 25.0M | 9.6M |
Investing Activities | |||||
Capital Expenditures | -47.9M | -55.7M | -30.9M | -46.7M | -1.2M |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -43.5M | -51.3M | -26.6M | -43.7M | 944.0K |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -107.0K | -10.4M | -10.4M | -10.3M | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | - | 0 |
Financing Cash Flow | -107.0K | -10.4M | -10.4M | -10.3M | 0 |
Free Cash Flow | -21.3M | 403.0K | 12.9M | -2.7M | 22.5M |
Net Change in Cash | -37.8M | -35.3M | -327.0K | -29.0M | 10.6M |
Cash Flow Trend
Lotus Eye Hospital Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
213.08
Price to Book
2.69
Price to Sales
3.18
Profitability Ratios
Profit Margin
1.32%
Operating Margin
4.86%
Return on Equity
1.23%
Return on Assets
1.06%
Financial Health
Current Ratio
1.56
Debt to Equity
5.72
Beta
0.43
Per Share Data
EPS (TTM)
₹0.36
Book Value per Share
₹28.54
Revenue per Share
₹24.39
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
lotuseye | 1.6B | 213.08 | 2.69 | 1.23% | 1.32% | 5.72 |
Max Healthcare | 1.2T | 104.16 | 12.65 | 11.47% | 15.27% | 32.09 |
Apollo Hospitals | 1.1T | 71.43 | 13.69 | 16.71% | 6.98% | 90.89 |
Indraprastha Medical | 41.8B | 24.93 | 7.02 | 26.98% | 12.21% | 5.49 |
Shalby | 21.9B | 1,128.89 | 2.00 | 0.63% | -0.05% | 47.82 |
Dr. Agarwal's Eye | 21.2B | 36.63 | 10.09 | 26.07% | 13.96% | 158.94 |
Financial data is updated regularly. All figures are in the company's reporting currency.